Corrigendum to “The untold story of IFN-γ in cancer biology” [Cytokine Growth Factor Rev. 31 (2016) 73–81] (S1359610116300727)(10.1016/j.cytogfr.2016.07.005);The untold story of IFN-γ in cancer biology

Cytokine and Growth Factor Reviews

Volumn 31, Issue , 2016, Pages 73-81

  Kursunel, M Alper ^a   Esendagli, Gunes ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anti tumor immunity; Cancer; Immune regulation; Immunotherapy; Interferon; Myeloid cell; T cell

Indexed keywords

BETA CATENIN; CASPASE 3; CASPASE 7; CASPASE 8; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 1; GAMMA INTERFERON RECEPTOR 2; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA CONVERTING ENZYME; JANUS KINASE 1; JANUS KINASE 2; MICRORNA 29A; MITOGEN ACTIVATED PROTEIN KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P16; PROTEIN P27; STAT1 PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

ANGIOGENESIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL EXPANSION; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVATION; FEEDBACK SYSTEM; GAMMA DELTA T LYMPHOCYTE; GLIOBLASTOMA; HOMEOSTASIS; HUMAN; IN VIVO STUDY; LIVER CELL CARCINOMA; MACROPHAGE; MELANOMA; METABOLIC REGULATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RETINOBLASTOMA; SHORT SURVEY; SIGNAL TRANSDUCTION; TH1 CELL; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; UTERINE CERVIX CARCINOMA IN SITU; IMMUNOLOGY;

HUMANS; INTERFERON-GAMMA; NEOPLASMS;

EID: 84994182440     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.02.002     Document Type: Erratum

References (205)

1. [1] Matzinger, P., The danger model: a renewed sense of self. Science 296 (2002), 301–305.
2. [2] Gilroy, D., De Maeyer, R., New insights into the resolution of inflammation. Semin. Immunol. 27 (2015), 161–168.
3. [3] Headland, S.E., Norling, L.V., The resolution of inflammation: principles and challenges. Semin. Immunol. 27 (2015), 149–160.
4. [4] Tam, J.C., Jacques, D.A., Intracellular immunity: finding the enemy within-how cells recognize and respond to intracellular pathogens. J. Leukoc. Biol. 96 (2014), 233–244.
5. [5] Billiau, A., Matthys, P., Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 20 (2009), 97–113.
6. [6] Frucht, D.M., Fukao, T., Bogdan, C., Schindler, H., O'Shea, J.J., Koyasu, S., IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 22 (2001), 556–560.
7. [7] Schroder, K., Hertzog, P.J., Ravasi, T., Hume, D.A., Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75 (2004), 163–189.
8. [8] Zitvogel, L., Tesniere, A., Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006), 715–727.
9. [9] Dunn, G.P., Old, L.J., Schreiber, R.D., The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004), 137–148.
10. [10] Schoenborn, J.R., Wilson, C.B., Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96 (2007), 41–101.
11. [11] Seliger, B., Ruiz-Cabello, F., Garrido, F., IFN inducibility of major histocompatibility antigens in tumors. Adv. Cancer Res. 101 (2008), 249–276.
12. [12] Dovhey, S.E., Ghosh, N.S., Wright, K.L., Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res. 60 (2000), 5789–5796.
13. [13] Dick, T.P., Ruppert, T., Groettrup, M., Kloetzel, P.M., Kuehn, L., Koszinowski, U.H., et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86 (1996), 253–262.
14. [14] Thelemann, C., Eren, R.O., Coutaz, M., Brasseit, J., Bouzourene, H., Rosa, M., et al. Interferon-gamma induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis. PLoS One, 9, 2014, e86844.
15. [15] Gosselin, E.J., Wardwell, K., Rigby, W.F., Guyre, P.M., Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J. Immunol. 151 (1993), 1482–1490.
16. [16] Bogdan, C., Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol. 36 (2015), 161–178.
17. [17] Trost, M., English, L., Lemieux, S., Courcelles, M., Desjardins, M., Thibault, P., The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30 (2009), 143–154.
18. [18] Dufour, J.H., Dziejman, M., Liu, M.T., Leung, J.H., Lane, T.E., Luster, A.D., IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168 (2002), 3195–3204.
19. [19] de Wit, H., Hoogstraten, D., Halie, R.M., Vellenga, E., Interferon-gamma modulates the lipopolysaccharide-induced expression of AP-1 and NF-kappa B at the mRNA and protein level in human monocytes. Exp. Hematol. 24 (1996), 228–235.
20. [20] Labeur, M., Refojo, D., Wolfel, B., Stalla, J., Vargas, V., Theodoropoulou, M., et al. Interferon-gamma inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. J. Endocrinol. 199 (2008), 177–189.
21. [21] Hiroi, M., Ohmori, Y., Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. Biochem. J. 376 (2003), 393–402.
22. [22] Karin, N., Wildbaum, G., The role of chemokines in shaping the balance between CD4(+) T cell subsets and its therapeutic implications in autoimmune and cancer diseases. Front. Immunol., 6, 2015, 609.
23. [23] Liu, J., Guan, X., Ma, X., Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J. Exp. Med. 204 (2007), 141–152.
24. [24] Curiel, R.E., Garcia, C.S., Rottschafer, S., Bosco, M.C., Espinoza-Delgado, I., Enhanced B7-2 gene expression by interferon-gamma in human monocytic cells is controlled through transcriptional and posttranscriptional mechanisms. Blood 94 (1999), 1782–1789.
25. [25] Deligne, C., Metidji, A., Fridman, W.H., Teillaud, J.L., Anti-CD20 therapy induces a memory Th1 response through the IFN-gamma/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia 29 (2015), 947–957.
26. [26] Zhu, J., Yamane, H., Paul, W.E., Differentiation of effector CD4T cell populations (*). Annu. Rev. Immunol. 28 (2010), 445–489.
27. [27] Ulloa, L., Doody, J., Massague, J., Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397 (1999), 710–713.
28. [28] Luheshi, N., Davies, G., Poon, E., Wiggins, K., McCourt, M., Legg, J., Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro. Eur. J. Immunol. 44 (2014), 162–172.
29. [29] Cope, A., Le Friec, G., Cardone, J., Kemper, C., The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. Trends Immunol. 32 (2011), 278–286.
30. [30] Sun, R., Luo, J., Li, D., Shu, Y., Luo, C., Wang, S.S., et al. Neutrophils with protumor potential could efficiently suppress tumor growth after cytokine priming and in presence of normal NK cells. Oncotarget 5 (2014), 12621–12634.
31. [31] Sarhan, D., D'Arcy, P., Wennerberg, E., Liden, M., Hu, J., Winqvist, O., et al. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-gamma. Eur. J. Immunol. 43 (2013), 249–257.
32. [32] Smyth, M.J., Cretney, E., Takeda, K., Wiltrout, R.H., Sedger, L.M., Kayagaki, N., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193 (2001), 661–670.
33. [33] Berthou, C., Bourge, J.F., Zhang, Y., Soulie, A., Geromin, D., Denizot, Y., et al. Interferon-gamma-induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis. Blood 95 (2000), 2329–2336.
34. [34] de Weerd, N.A., Nguyen, T., The interferons and their receptors–distribution and regulation. Immunol. Cell Biol. 90 (2012), 483–491.
35. [35] Hu, X., Ivashkiv, L.B., Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31 (2009), 539–550.
36. [36] Costa-Pereira, A.P., Williams, T.M., Strobl, B., Watling, D., Briscoe, J., Kerr, I.M., The antiviral response to gamma interferon. J. Virol. 76 (2002), 9060–9068.
37. [37] Matsuzaki, J., Tsuji, T., Luescher, I.F., Shiku, H., Mineno, J., Okamoto, S., et al. Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci. Rep., 5, 2015, 14896.
38. [38] Kortylewski, M., Komyod, W., Kauffmann, M.E., Bosserhoff, A., Heinrich, P.C., Behrmann, I., Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J. Invest. Dermatol. 122 (2004), 414–422.
39. [39] Kochupurakkal, B.S., Wang, Z.C., Hua, T., Culhane, A.C., Rodig, S.J., Rajkovic-Molek, K., et al. RelA-induced interferon response negatively regulates proliferation. PLoS One, 10, 2015, e0140243.
40. [40] Hydbring, P., Bahram, F., Su, Y., Tronnersjo, S., Hogstrand, K., von der Lehr, N., et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 58–63.
41. [41] Bahram, F., Hydbring, P., Tronnersjo, S., Zakaria, S.M., Frings, O., Fahlen, S., et al. Interferon-gamma-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation. Oncotarget 7 (2016), 2837–2854.
42. [42] Li, W., Huang, X., Tong, H., Wang, Y., Zhang, T., Wang, W., et al. Comparison of the regulation of beta-catenin signaling by type I, type II and type III interferons in hepatocellular carcinoma cells. PLoS One, 7, 2012, e47040.
43. [43] Wang, L., Wang, Y., Song, Z., Chu, J., Qu, X., Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J. Interferon Cytokine Res. 35 (2015), 273–280.
44. [44] Kominsky, S., Johnson, H.M., Bryan, G., Tanabe, T., Hobeika, A.C., Subramaniam, P.S., et al. IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1. Oncogene 17 (1998), 2973–2979.
45. [45] Burke, F., Smith, P.D., Crompton, M.R., Upton, C., Balkwill, F.R., Cytotoxic response of ovarian cancer cell lines to IFN-gamma is associated with sustained induction of IRF-1 and p21 mRNA. Br. J. Cancer 80 (1999), 1236–1244.
46. [46] Lee, S.H., Kim, J.W., Oh, S.H., Kim, Y.J., Rho, S.B., Park, K., et al. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. FEBS Lett. 579 (2005), 1027–1033.
47. [47] Braumuller, H., Wieder, T., Brenner, E., Assmann, S., Hahn, M., Alkhaled, M., et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494 (2013), 361–365.
48. [48] Schmitt, M.J., Philippidou, D., Reinsbach, S.E., Margue, C., Wienecke-Baldacchino, A., Nashan, D., et al. Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun Signal., 10, 2012, 41.
49. [49] Xu, X., Fu, X.Y., Plate, J., Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 58 (1998), 2832–2837.
50. [50] Shadrin, N., Shapira, M.G., Khalfin, B., Uppalapati, L., Parola, A.H., Nathan, I., Serine protease inhibitors interact with IFN-gamma through up-regulation of FasR; a novel therapeutic strategy against cancer. Exp. Cell Res. 330 (2015), 233–239.
51. [51] Lee, J.K., Sayers, T.J., Brooks, A.D., Back, T.C., Young, H.A., Komschlies, K.L., et al. IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J. Immunol. 164 (2000), 231–239.
52. [52] Ruiz-Ruiz, C., Lopez-Rivas, A., Mitochondria-dependent and −independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem. J 365 (2002), 825–832.
53. [53] Ruiz-Ruiz, C., Ruiz de Almodovar, C., Rodriguez, A., Ortiz-Ferron, G., Redondo, J.M., Lopez-Rivas, A., The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J. Biol. Chem. 279 (2004), 19712–19720.
54. [54] Stang, M.T., Armstrong, M.J., Watson, G.A., Sung, K.Y., Liu, Y., Ren, B., et al. Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells. Oncogene 26 (2007), 6420–6430.
55. [55] Pizzoferrato, E., Liu, Y., Gambotto, A., Armstrong, M.J., Stang, M.T., Gooding, W.E., et al. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res. 64 (2004), 8381–8388.
56. [56] Ning, Y., Riggins, R.B., Mulla, J.E., Chung, H., Zwart, A., Clarke, R., IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. Mol. Cancer Ther. 9 (2010), 1274–1285.
57. [57] Detjen, K.M., Farwig, K., Welzel, M., Wiedenmann, B., Rosewicz, S., Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 49 (2001), 251–262.
58. [58] Barthson, J., Germano, C.M., Moore, F., Maida, A., Drucker, D.J., Marchetti, P., et al. Cytokines tumor necrosis factor-alpha and interferon-gamma induce pancreatic beta-cell apoptosis through STAT1-mediated Bim protein activation. J. Biol. Chem. 286 (2011), 39632–39643.
59. [59] Tateishi, K., Ohta, M., Guleng, B., Kanai, F., Tanaka, Y., Asaoka, Y., et al. TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors. Int. J. Cancer 118 (2006), 2237–2246.
60. [60] George, J., Banik, N.L., Ray, S.K., Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clin. Cancer Res. 15 (2009), 7186–7195.
61. [61] Fathallah-Shaykh, H.M., Zhao, L.J., Kafrouni, A.I., Smith, G.M., Forman, J., Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J. Immunol. 164 (2000), 217–222.
62. [62] Beatty, G., Paterson, Y., IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J. Immunol. 166 (2001), 2276–2282.
63. [63] Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 7556–7561.
64. [64] Dunn, G.P., Koebel, C.M., Schreiber, R.D., Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006), 836–848.
65. [65] Windbichler, G.H., Hausmaninger, H., Stummvoll, W., Graf, A.H., Kainz, C., Lahodny, J., et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82 (2000), 1138–1144.
66. [66] Giannopoulos, A., Constantinides, C., Fokaeas, E., Stravodimos, C., Giannopoulou, M., Kyroudi, A., et al. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin. Cancer Res. 9 (2003), 5550–5558.
67. [67] Creagan, E.T., Schaid, D.J., Ahmann, D.L., Frytak, S., Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. J. Invest. Dermatol. 95 (1990), 188S–192S.
68. [68] Talpaz, M., Kurzrock, R., Kantarjian, H., Rothberg, J., Saks, S., Evans, L., et al. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer 68 (1991), 2125–2130.
69. [69] Schiller, J.H., Storer, B., Dreicer, R., Rosenquist, D., Frontiera, M., Carbone, P.P., Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J. Natl. Cancer Inst. 81 (1989), 1739–1743.
70. [70] Jett, J.R., Maksymiuk, A.W., Su, J.Q., Mailliard, J.A., Krook, J.E., Tschetter, L.K., et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J. Clin. Oncol. 12 (1994), 2321–2326.
71. [71] Von Hoff, D.D., Fleming, T.R., Macdonald, J.S., Goodman, P.J., Van Damme, J., Brown, T.D., et al. Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study. J. Biol. Response Mod. 9 (1990), 584–587.
72. [72] Brown, T.D., Goodman, P.J., Fleming, T., Macdonald, J.S., O'Rourke, T., Taylor, S.A., et al. Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. J Immunother <***>(1991) 10 (1991), 379–382.
73. [73] Mahjoubi, R., Bachouchi, M., Munck, J.N., Busson, P., Gasmi, J., Azli, N., et al. Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head Neck 15 (1993), 115–118.
74. [74] Vahdat, L.T., Cohen, D.J., Zipin, D., Lo, K.S., Donovan, D., Savage, D., et al. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone Marrow Transplant. 40 (2007), 267–272.
75. [75] Gleave, M.E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma: canadian Urologic Oncology Group. N. Engl. J. Med. 338 (1998), 1265–1271.
76. [76] Babjuk, M., Burger, M., Zigeuner, R., Shariat, S.F., van Rhijn, B.W., Comperat, E., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64 (2013), 639–653.
77. [77] Brill, T.H., Kubler, H.R., von Randenborgh, H., Fend, F., Pohla, H., Breul, J., et al. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer-a phase I clinical trial. J. Gene Med. 9 (2007), 547–560.
78. [78] Hildenbrand, B., Sauer, B., Kalis, O., Stoll, C., Freudenberg, M.A., Niedermann, G., et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells–a pilot study. Prostate 67 (2007), 500–508.
79. [79] Donia, M., Hansen, M., Sendrup, S.L., Iversen, T.Z., Ellebaek, E., Andersen, M.H., et al. Methods to improve adoptive T-cell therapy for melanoma: IFN-gamma enhances anticancer responses of cell products for infusion. J. Invest. Dermatol. 133 (2013), 545–552.
80. [80] Alberts, D.S., Marth, C., Alvarez, R.D., Johnson, G., Bidzinski, M., Kardatzke, D.R., et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol. Oncol. 109 (2008), 174–181.
81. [81] Marth, C., Windbichler, G.H., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A., et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16 (2006), 1522–1528.
82. [82] Khammari, A., Nguyen, J.M., Saint-Jean, M., Knol, A.C., Pandolfino, M.C., Quereux, G., et al. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients. Cancer Immunol. Immunother. 64 (2015), 805–815.
83. [83] Taniguchi, K., Petersson, M., Hoglund, P., Kiessling, R., Klein, G., Karre, K., Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. U. S. A. 84 (1987), 3405–3409.
84. [84] Lollini, P.L., Bosco, M.C., Cavallo, F., De Giovanni, C., Giovarelli, M., Landuzzi, L., et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer 55 (1993), 320–329.
85. [85] Arzt, L., Kothmaier, H., Halbwedl, I., Quehenberger, F., Popper, H.H., Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma. Virchows Arch. 465 (2014), 79–88.
86. [86] Kharma, B., Baba, T., Matsumura, N., Kang, H.S., Hamanishi, J., Murakami, R., et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res. 74 (2014), 6519–6530.
87. [87] Khodarev, N., Ahmad, R., Rajabi, H., Pitroda, S., Kufe, T., McClary, C., et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 29 (2010), 920–929.
88. [88] Brandacher, G., Winkler, C., Schroecksnadel, K., Margreiter, R., Fuchs, D., Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr. Drug Metab. 7 (2006), 599–612.
89. [89] Zuo, H., Tell, G.S., Vollset, S.E., Ueland, P.M., Nygard, O., Midttun, O., et al. Interferon-gamma-induced inflammatory markers and the risk of cancer: the Hordaland Health Study. Cancer 120 (2014), 3370–3377.
90. [90] U.S. National Institutes of Health, Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma. 2016 (accessed 03.07.16) https://clinicaltrials.gov/ct2/show/study/NCT01957709/.
91. [91] U.S. National Institutes of Health, A Study of the Efficacy and Safety of Asn-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma (ASN-002-001). 2016 (accessed 03.07.16) https://clinicaltrials.gov/ct2/show/NCT02550678/.
92. [92] U.S. National Institutes of Health, Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors. 2015 (accessed 03.07.16) https://clinicaltrials.gov/ct2/show/NCT02614456/.
93. [93] U.S. National Institutes of Health, DNX-2401 With Interferon Gamma (IFN-() for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I). 2016 (accessed 03.07.16) https://clinicaltrials.gov/ct2/show/NCT02197169/.
94. [94] Becker, C., Pohla, H., Frankenberger, B., Schuler, T., Assenmacher, M., Schendel, D.J., et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. 7 (2001), 1159–1162.
95. [95] Besser, M.J., Shapira-Frommer, R., Treves, A.J., Zippel, D., Itzhaki, O., Schallmach, E., et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J. Immunother. 32 (2009), 415–423.
96. [96] Ullenhag, G.J., Sadeghi, A.M., Carlsson, B., Ahlstrom, H., Mosavi, F., Wagenius, G., et al. Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol. Immunother. 61 (2012), 725–732.
97. [97] Hillerdal, V., Ramachandran, M., Leja, J., Essand, M., Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer, 14, 2014, 30.
98. [98] Ishikawa, T., Kokura, S., Sakamoto, N., Okayama, T., Endo, M., Tsuchiya, R., et al. Whole blood interferon-gamma levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer. Int. J. Cancer 133 (2013), 1119–1125.
99. [99] Marth, C., Fiegl, H., Zeimet, A.G., Muller-Holzner, E., Deibl, M., Doppler, W., et al. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am. J. Obstet. Gynecol. 191 (2004), 1598–1605.
100. [100] Spear, P., Barber, A., Sentman, C.L., Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology, 2, 2013, e23564.
101. [101] Laurin, D., Marin, V., Biagi, E., Pizzitola, I., Agostoni, V., Gallot, G., et al. Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor. J. Immunother. 36 (2013), 181–189.
102. [102] Textor, A., Listopad, J.J., Wuhrmann, L.L., Perez, C., Kruschinski, A., Chmielewski, M., et al. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNgamma. Cancer Res. 74 (2014), 6796–6805.
103. [103] Amos, S.M., Duong, C.P., Westwood, J.A., Ritchie, D.S., Junghans, R.P., Darcy, P.K., et al. Autoimmunity associated with immunotherapy of cancer. Blood 118 (2011), 499–509.
104. [104] Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
105. [105] Barrett, D.M., Teachey, D.T., Grupp, S.A., Toxicity management for patients receiving novel T-cell engaging therapies. Curr. Opin. Pediatr. 26 (2014), 43–49.
106. [106] Ravelli, A., Grom, A.A., Behrens, E.M., Cron, R.Q., Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 13 (2012), 289–298.
107. [107] Schulert, G.S., Grom, A.A., Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu. Rev. Med. 66 (2015), 145–159.
108. [108] Maude, S.L., Barrett, D., Teachey, D.T., Grupp, S.A., Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20 (2014), 119–122.
109. [109] Kmieciak, M., Payne, K.K., Wang, X.Y., Manjili, M.H., IFN-gamma Ralpha is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PLoS One, 8, 2013, e82544.
110. [110] Osborn, J.L., Greer, S.F., Metastatic melanoma cells evade immune detection by silencing STAT1. Int. J. Mol. Sci. 16 (2015), 4343–4361.
111. [111] Andreev, K., Trufa, I.D., Siegemund, R., Rieker, R., Hartmann, A., Schmidt, J., et al. Impaired T-bet-pSTAT1alpha and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma. Br. J. Cancer 113 (2015), 902–913.
112. [112] Tseng, P.C., Huang, W.C., Chen, C.L., Sheu, B.S., Shan, Y.S., Tsai, C.C., et al. Regulation of SHP2 by PTEN/AKT/GSK-3beta signaling facilitates IFN-gamma resistance in hyperproliferating gastric cancer. Immunobiology 217 (2012), 926–934.
113. [113] Murtas, D., Maric, D., De Giorgi, V., Reinboth, J., Worschech, A., Fetsch, P., et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. Br. J. Cancer 109 (2013), 76–82.
114. [114] Souckova, K., Kovarik, A., Dusek, L., Humpolikova-Adamkova, L., Lauerova, L., Krejci, E., et al. Reduced inducibility of SOCS3 by interferon gamma associates with higher resistance of human breast cancer lines as compared to normal mammary epithelial cells. Neoplasma 56 (2009), 379–386.
115. [115] You, M., Yu, D.H., Feng, G.S., Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19 (1999), 2416–2424.
116. [116] Yim, J.H., Wu, S.J., Lowney, J.K., Vander Velde, T.L., Doherty, G.M., Enhancing in vivo tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous IFN-gamma. J. Interferon Cytokine Res. 19 (1999), 723–729.
117. [117] Heinonen, K.M., Bourdeau, A., Doody, K.M., Tremblay, M.L., Protein tyrosine phosphatases PTP-1B and TC-PTP play nonredundant roles in macrophage development and IFN-gamma signaling. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 9368–9372.
118. [118] Laner-Plamberger, S., Wolff, F., Kaser-Eichberger, A., Swierczynski, S., Hauser-Kronberger, C., Frischauf, A.M., et al. Hedgehog/GLI signaling activates suppressor of cytokine signaling 1 (SOCS1) in epidermal and neural tumor cells. PLoS One, 8, 2013, e75317.
119. [119] Urbschat, A., Stumpf, S., Hanze, J., Paulus, P., Maier, T.J., Weipert, C., et al. Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma. Tumour Biol., 2016.
120. [120] Chen, C.L., Chiang, T.H., Tseng, P.C., Wang, Y.C., Lin, C.F., Loss of PTEN causes SHP2 activation, making lung cancer cells unresponsive to IFN-gamma. Biochem. Biophys. Res. Commun. 466 (2015), 578–584.
121. [121] Cui, L., Deng, Y., Rong, Y., Lou, W., Mao, Z., Feng, Y., et al. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 33 (2012), 247–255.
122. [122] Pestka, S., Krause, C.D., Walter, M.R., Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202 (2004), 8–32.
123. [123] Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget 5 (2014), 12189–12202.
124. [124] S. Pensa, G. Regis, D. Boselli, et al., STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin? In: Madame Curie Bioscience Database [Internet] Austin (TX): Landes Bioscience; 2000–2013.
125. [125] Nees, M., Geoghegan, J.M., Hyman, T., Frank, S., Miller, L., Woodworth, C.D., Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75 (2001), 4283–4296.
126. [126] Hodge, G., Barnawi, J., Jurisevic, C., Moffat, D., Holmes, M., Reynolds, P.N., et al. Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-gamma by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin. Exp. Immunol. 178 (2014), 79–85.
127. [127] Sarmadi, P., Tunali, G., Esendagli-Yilmaz, G., Yilmaz, K.B., Esendagli, G., CRAM-A indicates IFN-gamma-associated inflammatory response in breast cancer. Mol. Immunol. 68 (2015), 692–698.
128. [128] Street, S.E., Cretney, E., Smyth, M.J., Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97 (2001), 192–197.
129. [129] Turhan, N., Esendagli, G., Ozkayar, O., Tunali, G., Sokmensuer, C., Abbasoglu, O., Co-existence of Echinococcus granulosus infection and cancer metastasis in the liver correlates with reduced Th1 immune responses. Parasite Immunol. 37 (2015), 16–22.
130. [130] Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med., 5, 2013, 200ra116.
131. [131] Ness, N., Andersen, S., Valkov, A., Nordby, Y., Donnem, T., Al-Saad, S., et al. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate 74 (2014), 1452–1461.
132. [132] Karasar, P., Esendagli, G.T., helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res. Treat. 145 (2014), 605–614.
133. [133] Dolen, Y., Esendagli, G., Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur. J. Immunol. 43 (2013), 747–757.
134. [134] Hu, T., Yang, P., Zhu, H., Chen, X., Xie, X., Yang, M., et al. Accumulation of invariant NKT cells with increased IFN-gamma production in persistent high-risk HPV-infected high-grade cervical intraepithelial neoplasia. Diagn. Pathol., 10, 2015, 20.
135. [135] White, M.J., McArthur, K., Metcalf, D., Lane, R.M., Cambier, J.C., Herold, M.J., et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 159 (2014), 1549–1562.
136. [136] Souza-Fonseca-Guimaraes, F., Parlato, M., de Oliveira, R.B., Golenbock, D., Fitzgerald, K., Shalova, I.N., et al. Interferon-gamma and granulocyte/monocyte colony-stimulating factor production by natural killer cells involves different signaling pathways and the adaptor stimulator of interferon genes (STING). J. Biol. Chem. 288 (2013), 10715–10721.
137. [137] Temizoz, B., Kuroda, E., Ohata, K., Jounai, N., Ozasa, K., Kobiyama, K., et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur. J. Immunol. 45 (2015), 1159–1169.
138. [138] Burgler, S., Gimeno, A., Parente-Ribes, A., Wang, D., Os, A., Devereux, S., et al. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-gamma by a T-bet-dependent mechanism. J. Immunol. 194 (2015), 827–835.
139. [139] Tanese, K., Hashimoto, Y., Berkova, Z., Wang, Y., Samaniego, F., Lee, J.E., et al. Cell surface CD74-MIF interactions drive melanoma survival in response to interferon-gamma. J. Invest. Dermatol. 135 (2015), 2775–2784.
140. [140] Weichselbaum, R.R., Ishwaran, H., Yoon, T., Nuyten, D.S., Baker, S.W., Khodarev, N., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 18490–18495.
141. [141] Pettit, S.J., Seymour, K., O'Flaherty, E., Kirby, J.A., Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br. J. Cancer 82 (2000), 1900–1906.
142. [142] Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008), 677–704.
143. [143] Yao, S., Chen, L., PD-1 as an immune modulatory receptor. Cancer J. 20 (2014), 262–264.
144. [144] Juno, J.A., Stalker, A.T., Waruk, J.L., Oyugi, J., Kimani, M., Plummer, F.A., et al. Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment. Retrovirology, 12, 2015, 17.
145. [145] Benson, D.M. Jr., Bakan, C.E., Mishra, A., Hofmeister, C.C., Efebera, Y., Becknell, B., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116 (2010), 2286–2294.
146. [146] Huang, B.Y., Zhan, Y.P., Zong, W.J., Yu, C.J., Li, J.F., Qu, Y.M., et al. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. PLoS One, 10, 2015, e0134715.
147. [147] Qu, Q.X., Huang, Q., Shen, Y., Zhu, Y.B., Zhang, X.G., The increase of circulating PD-L1-expressing CD68 macrophage in ovarian cancer. Tumour Biol., 2015.
148. [148] Ritprajak, P., Azuma, M., Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 51 (2015), 221–228.
149. [149] Wolfle, S.J., Strebovsky, J., Bartz, H., Sahr, A., Arnold, C., Kaiser, C., et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol. 41 (2011), 413–424.
150. [150] Yao, S., Chen, L., Adaptive resistance: a tumor strategy to evade immune attack. Eur. J. Immunol. 43 (2013), 576–579.
151. [151] Rozali, E.N., Hato, S.V., Robinson, B.W., Lake, R.A., Lesterhuis, W.J., Programmed death ligand 2 in cancer-induced immune suppression. Clin. Dev. Immunol., 2012, 2012, 656340.
152. [152] Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112 (2015), 1501–1509.
153. [153] Jiang, D., Xu, Y.Y., Li, F., Xu, B., Zhang, X.G., The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism. Med. Oncol., 31, 2014, 268.
154. [154] Soliman, H., Khalil, F., Antonia, S., PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One, 9, 2014, e88557.
155. [155] Qiao, G., Yang, L., Li, Z., Ying, H., Hassen, Y., Yin, F., et al. Program death-1 regulates peripheral T cell tolerance via an anergy-independent mechanism. Clin. Immunol. 143 (2012), 128–133.
156. [156] Wherry, E.J., T cell exhaustion. Nat. Immunol. 12 (2011), 492–499.
157. [157] Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
158. [158] Lim, S.H., Sun, J.M., Lee, S.H., Ahn, J.S., Park, K., Ahn, M.J., Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin. Biol. Ther. 16 (2016), 397–406.
159. [159] Lehnert, C., Weiswange, M., Jeremias, I., Bayer, C., Grunert, M., Debatin, K.M., et al. TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation. J. Immunol. 193 (2014), 4021–4031.
160. [160] Koyama, S., Koike, N., Adachi, S., Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J. Cancer Res. Clin. Oncol. 128 (2002), 73–79.
161. [161] Refaeli, Y., Van Parijs, L., Alexander, S.I., Abbas, A.K., Interferon gamma is required for activation-induced death of T lymphocytes. J. Exp. Med. 196 (2002), 999–1005.
162. [162] Chow, W.A., Fang, J.J., Yee, J.K., The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J. Immunol. 164 (2000), 3512–3518.
163. [163] Crawford, A., Angelosanto, J.M., Kao, C., Doering, T.A., Odorizzi, P.M., Barnett, B.E., et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40 (2014), 289–302.
164. [164] Crespo, J., Sun, H., Welling, T.H., Tian, Z., cell anergy, Zou W.T., exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25 (2013), 214–221.
165. [165] Speiser, D.E., Utzschneider, D.T., Oberle, S.G., Munz, C., Romero, P., Zehn, D., T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion. Nat. Rev. Immunol. 14 (2014), 768–774.
166. [166] Japp, A.S., Kursunel, M.A., Meier, S., Malzer, J.N., Li, X., Rahman, N.A., et al. Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. Cancer Immunol. Immunother. 64 (2015), 1487–1494.
167. [167] Yang, Z.Z., Grote, D.M., Ziesmer, S.C., Niki, T., Hirashima, M., Novak, A.J., et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 122 (2012), 1271–1282.
168. [168] Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71 (2011), 5393–5399.
169. [169] Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
170. [170] Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J., Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29 (2011), 235–271.
171. [171] Yokozeki, H., Katayama, I., Ohki, O., Arimura, M., Takayama, K., Matsunaga, T., et al. Interferon-gamma differentially regulates CD80 (B7-1) and CD86 (B7-2/B70) expression on human Langerhans cells. Br. J. Dermatol. 136 (1997), 831–837.
172. [172] Markel, G., Seidman, R., Cohen, Y., Besser, M.J., Sinai, T.C., Treves, A.J., et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126 (2009), 186–200.
173. [173] Gencheva, M., Chen, C.J., Nguyen, T., Shively, J.E., Regulation of CEACAM1 transcription in human breast epithelial cells. BMC Mol. Biol., 11, 2010, 79.
174. [174] Andreae, S., Buisson, S., Triebel, F., MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102 (2003), 2130–2137.
175. [175] Hemon, P., Jean-Louis, F., Ramgolam, K., Brignone, C., Viguier, M., Bachelez, H., et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J. Immunol. 186 (2011), 5173–5183.
176. [176] Huang, Y.H., Zhu, C., Kondo, Y., Anderson, A.C., Gandhi, A., Russell, A., et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517 (2015), 386–390.
177. [177] Ndhlovu, L.C., Lopez-Verges, S., Barbour, J.D., Jones, R.B., Jha, A.R., Long, B.R., et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119 (2012), 3734–3743.
178. [178] Xu, L., Huang, Y., Tan, L., Yu, W., Chen, D., Lu, C., et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int. Immunopharmacol. 29 (2015), 635–641.
179. [179] Wastowski, I.J., Simoes, R.T., Yaghi, L., Donadi, E.A., Pancoto, J.T., Poras, I., et al. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-gamma treatments: results from a multicentric study. Am. J. Pathol. 182 (2013), 540–552.
180. [180] Sikalidis, A.K., Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer. Pathol. Oncol. Res. 21 (2015), 9–17.
181. [181] Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190 (2013), 3783–3797.
182. [182] Clara, R.O., Assmann, N., Ramos Moreno, A.C., Coimbra, J.B., Nurenberger, N., Dettmer-Wilde, K., et al. Melanocytes are more responsive to IFN-gamma and produce higher amounts of kynurenine than melanoma cells. Biol. Chem. 397 (2016), 85–90.
183. [183] Maldonado, R.A., von Andrian, U.H., How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108 (2010), 111–165.
184. [184] He, Y.W., Wang, H.S., Zeng, J., Fang, X., Chen, H.Y., Du, J., et al. Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells. Life Sci. 93 (2013), 509–515.
185. [185] Sharda, D.R., Yu, S., Ray, M., Squadrito, M.L., De Palma, M., Wynn, T.A., et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J. Immunol. 187 (2011), 2181–2192.
186. [186] Wei LH, Jacobs AT, Morris SM, Jr., Ignarro LJ. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2000;279:C248-56.
187. [187] Morris, S.M. Jr., Kepka-Lenhart, D., Chen, L.C., Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am. J. Physiol. 275 (1998), E740–7.
188. [188] Kim, J., Yoon, Y., Jeoung, D., Kim, Y.M., Choe, J., Interferon-gamma stimulates human follicular dendritic cell-like cells to produce prostaglandins via the JAK-STAT pathway. Mol. Immunol. 66 (2015), 189–196.
189. [189] Talmadge, J.E., Gabrilovich, D.I., History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13 (2013), 739–752.
190. [190] Schouppe, E., Mommer, C., Movahedi, K., Laoui, D., Morias, Y., Gysemans, C., et al. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur. J. Immunol. 43 (2013), 2930–2942.
191. [191] Zhan, X., Fang, Y., Hu, S., Wu, Y., Yang, K., Liao, C., et al. IFN-gamma differentially regulates subsets of Gr-1(+)CD11b(+) myeloid cells in chronic inflammation. Mol. Immunol. 66 (2015), 451–462.
192. [192] Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
193. [193] Nagaraj, S., Schrum, A.G., Cho, H.I., Celis, E., Gabrilovich, D.I., Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184 (2010), 3106–3116.
194. [194] Zhang, Y., Choksi, S., Chen, K., Pobezinskaya, Y., Linnoila, I., Liu, Z.G., ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 23 (2013), 898–914.
195. [195] Zea, A.H., Aiyar, A., Tate, D., Dual effect of interferon (IFNgamma)-induced nitric oxide on tumorigenesis and intracellular bacteria. Vitam. Horm. 96 (2014), 299–321.
196. [196] Schuettpelz, L.G., Link, D.C., Regulation of hematopoietic stem cell activity by inflammation. Front. Immunol., 4, 2013, 204.
197. [197] Ueha, S., Shand, F.H., Matsushima, K., Myeloid cell population dynamics in healthy and tumor-bearing mice. Int. Immunopharmacol. 11 (2011), 783–788.
198. [198] Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181 (2008), 5791–5802.
199. [199] Haverkamp, J.M., Crist, S.A., Elzey, B.D., Cimen, C., Ratliff, T.L., In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur. J. Immunol. 41 (2011), 749–759.
200. [200] Gallina, G., Dolcetti, L., Serafini, P., De Santo, C., Marigo, I., Colombo, M.P., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116 (2006), 2777–2790.
201. [201] Lin, F.C., Karwan, M., Saleh, B., Hodge, D.L., Chan, T., Boelte, K.C., et al. IFN-gamma causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood 124 (2014), 3699–3708.
202. [202] Medina-Echeverz, J., Haile, L.A., Zhao, F., Gamrekelashvili, J., Ma, C., Metais, J.Y., et al. IFN-gamma regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1. Eur. J. Immunol. 44 (2014), 2457–2467.
203. [203] Lim, H.X., Hong, H.J., Cho, D., Kim, T.S., IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells. J. Immunol. 193 (2014), 5453–5460.
204. [204] Hix, L.M., Karavitis, J., Khan, M.W., Shi, Y.H., Khazaie, K., Zhang, M., Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J. Biol. Chem. 288 (2013), 11676–11688.
205. [205] Hosoi, A., Matsushita, H., Shimizu, K., Fujii, S., Ueha, S., Abe, J., et al. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int. J. Cancer 134 (2014), 1810–1822.